Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
Hosted on MSN13h
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback